---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030345"
form_type: "8-K/A"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T22:59:11.842036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences discloses CEO Richard Barry compensation: $675k base, 600k options at $27.42

## Summary
- Base salary $675,000, retroactive to July 15, 2024; annual bonus target 60% of base salary.
- Stock option award of 600,000 shares at $27.42 exercise price; vests 25% annually starting July 15, 2025.
- Termination without cause or for good reason triggers 12-month base salary continuation plus health benefits.
- Options granted under 2018 Omnibus Equity Incentive Plan; change-in-control triggers same severance.
- Agreement includes standard confidentiality, non-disclosure, and mandatory arbitration provisions.

## SEC filing metadata
- accession: 0001437749-24-030345
- form_type: 8-K/A
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030345/0001437749-24-030345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030345/sava20240930_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030345
- JSON: https://secwatch.observer/filing/0001437749-24-030345.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.